A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Clinical trial NCT01993212 · COMPLETED
Trial details
- NCT number
- NCT01993212
- Sponsor
- Repros Therapeutics Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-01-01
- Primary completion
- 2014-09-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.